Fragile X, page-5

This is a big deal and not far away either... If they kick this through the posts like they did with RETTS

Then NEU is really on the radar...

IT SEEMS TO WORK IN FX.

from Stewet Roberts Ballieu Holst Report.

 NNZ-2566 seems to work in Fragile X syndrome. In late 2012 Neuren unveiled preclinical evidence that NNZ-2566 worked to reduce the symptoms and biological abnormalities of Fragile X. This disorder, caused by mutations in the fmr1 gene on the X chromosome, is characterised by intellectual disability, hyperactive behaviour, social withdrawal and seizures. The attraction of Fragile X for Neuren is that large pharma companies including Novartis and Roche have looked seriously at the condition, which could enhance Neuren’s licensing prospects, while Neuren’s work on Fragile X has also attracted the support of the Fragile X Research Alliance and the Fragile X Drug Validation Initiative. Neuren’s Phase II double-blind, placebo-controlled clinical trial of NNZ-2566 in Fragile X, which is enrolling 60 subjects over six sites, is expected to yield top-line data in the first half of 2015. Fragile X, with an estimated US patient population of ~70,000, will be another Orphan indication for NNZ-2566. Neuren received Fast Track and Orphan Drug status for NNZ-2566 in Fragile X in October 2013.